Innovimmune Biotherapeutics Overview
- Year Founded
-
2010
- Status
-
Private
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
3
Innovimmune Biotherapeutics General Information
Description
Developer of novel oral small-molecule immunomodulatory drugs designed to treat cancer, autoimmune diseases, and chronic inflammation using AI-driven structure-guided drug design. The company develops proprietary New Chemical Entity immunotherapies utilizing AI-driven, structure-guided drug design to turn historically untargetable disease-causing proteins into viable druggable targets, enabling clients to access a pipeline in a molecule approach that advances single drug candidates across multiple therapeutic indications simultaneously
Contact Information
Website
www.innovimmune.comCorporate Office
- 75 Wall Street
- New York, NY 10005
- United States
Corporate Office
- 75 Wall Street
- New York, NY 10005
- United States
Innovimmune Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 2. Grant | 25-Jul-2014 | Completed | Generating Revenue | |||
| 1. Grant | 01-Jan-2011 | $600K | Completed | Generating Revenue |
Innovimmune Biotherapeutics Comparisons
Industry
Financing
Details
Innovimmune Biotherapeutics Competitors (72)
One of Innovimmune Biotherapeutics’s 72 competitors is Adiso Therapeutics, a Venture Capital-Backed company based in Newton, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Adiso Therapeutics | Venture Capital-Backed | Newton, MA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Apogee Therapeutics | Formerly VC-backed | Waltham, MA |
Innovimmune Biotherapeutics Patents
Innovimmune Biotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2696682-A2 | Mif inhibitors and their uses | Active | 13-Apr-2011 | ||
| EP-2696682-A4 | Mif inhibitors and their uses | Active | 13-Apr-2011 | ||
| EP-2696682-B1 | Mif inhibitors and their uses | Inactive | 13-Apr-2011 | ||
| EP-3354640-A2 | Mif inhibitors and their uses | Inactive | 13-Apr-2011 | ||
| EP-3354640-A3 | Mif inhibitors and their uses | Inactive | 13-Apr-2011 | C07D401/12 |
Innovimmune Biotherapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Institute Of Allergy and Infectious Diseases | Government | |||
| U.S. Department of Health and Human Services | Government | |||
| Start-up NY | Accelerator/Incubator | Minority |
Innovimmune Biotherapeutics FAQs
-
When was Innovimmune Biotherapeutics founded?
Innovimmune Biotherapeutics was founded in 2010.
-
Where is Innovimmune Biotherapeutics headquartered?
Innovimmune Biotherapeutics is headquartered in New York, NY.
-
What industry is Innovimmune Biotherapeutics in?
Innovimmune Biotherapeutics’s primary industry is Biotechnology.
-
Is Innovimmune Biotherapeutics a private or public company?
Innovimmune Biotherapeutics is a Private company.
-
What is Innovimmune Biotherapeutics’s current revenue?
The current revenue for Innovimmune Biotherapeutics is .
-
Who are Innovimmune Biotherapeutics’s investors?
National Institute Of Allergy and Infectious Diseases, U.S. Department of Health and Human Services, and Start-up NY have invested in Innovimmune Biotherapeutics.
-
Who are Innovimmune Biotherapeutics’s competitors?
Adiso Therapeutics, CytomX Therapeutics, Sorrento Therapeutics, Adaptimmune Therapeutics, and Apogee Therapeutics are some of the 72 competitors of Innovimmune Biotherapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process